UK Government Seeks Pharmaceutical Sector's Views on Regulation Enforcement - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

UK Government Seeks Pharmaceutical Sector's Views on Regulation Enforcement


The UK Department for Business Innovation & Skills is conducting a review of how well national regulators and local authorities enforce rules governing the pharmaceutical sector, and the group is seeking input from pharmaceutical producers, the department announced in a press release. The Focus on Enforcement review will be open for comment on the website and via email until September 2, 2013. The reviewers will also speak with individual businesses, trade bodies, and regulators. A response from regulators will follow the evidence-gathering phase of the review.

Ministers want to hear about any unnecessary burdens that are being placed on businesses and any duplication or inconsistencies between regulatory bodies. The review also seeks to find out whether companies are receiving the clear guidance they need to comply with the law. Firms are also invited to identify areas of good enforcement practice which could be replicated elsewhere.

“The UK pharmaceutical industry is a vital player in an increasingly competitive international market.  We must maximize its potential to attract investment, innovate, and create jobs, while maintaining world-class quality and safety standards,” said business minister Michael Fallon in the press release. “I want firms to tell us how we can improve the environment in which they work.  We want to make sure regulation is proportionately and intelligently applied to facilitate their contribution to our economy.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here